Bronchodilator Drugs - Argentina

Argentina

In Argentina, the revenue in the Bronchodilator Drugs market is projected to reach €102.10m in 2024.
It is expected to show an annual growth rate (CAGR 2024-2029) of 3.11%, resulting in a market volume of €119.00m by 2029.
When compared globally, United States is expected to generate the highest revenue of €15,910.00m in 2024.
Argentina is experiencing a growing demand for bronchodilator drugs due to the high prevalence of respiratory conditions in the country.

Key regions: United States, Europe, Brazil, Japan, United Kingdom

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

Bronchodilator drugs are a crucial component in the treatment of respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). In Argentina, the market for these drugs has shown significant growth in recent years, driven by various factors.

Customer preferences: The increasing prevalence of respiratory diseases in Argentina has led to a rise in demand for bronchodilator drugs. Patients suffering from these diseases require long-term treatment, which has resulted in a steady demand for these drugs. Additionally, the availability of a wide range of bronchodilator drugs has allowed patients to choose from various options based on their preferences and medical requirements.

Trends in the market: One of the significant trends in the bronchodilator drugs market in Argentina is the increasing adoption of combination therapies. These therapies combine two or more bronchodilator drugs to provide better treatment outcomes. The use of combination therapies has become increasingly popular in recent years, as they offer a more comprehensive approach to treating respiratory diseases.Another trend in the market is the growing preference for long-acting bronchodilators over short-acting ones. Long-acting bronchodilators provide sustained relief from respiratory symptoms and reduce the frequency of exacerbations. This has led to an increase in demand for these drugs, as they offer improved patient outcomes.

Local special circumstances: Argentina has a high prevalence of respiratory diseases, with asthma and COPD being the most common. The country's high smoking rates and poor air quality have contributed to the rise in respiratory diseases. These factors have created a significant demand for bronchodilator drugs in the country.

Underlying macroeconomic factors: The Argentinean pharmaceutical industry has been growing steadily, driven by factors such as an aging population and increasing healthcare spending. The government's efforts to improve access to healthcare have also contributed to the growth of the industry. Additionally, the country's favorable regulatory environment has encouraged investment in the pharmaceutical sector, leading to the introduction of new and innovative drugs in the market. These factors have created a conducive environment for the growth of the bronchodilator drugs market in Argentina.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.